NSE 500 — The Filing Layer   CompaniesCoverageDocument library

Sun Pharmaceutical Industries Ltd.

SUNPHARMAHealthcareR3 verified document library

Coverage

DatasetOn diskUsableState
Results XBRL (NSE + BSE)1033434 quarter-ends
Annual reports1111identity graded
Earnings calls2323transcripts and analyst meets only
Shareholding2020
Related party55
Investor decks6868

Financial statements (verified v2 store)

Quarterly values as filed, in INR crore, from the results XBRL; each cell carries its source instance and context in the cell title. Verification: 500 random source re-reads, 500 agree; identity failures 0. Ratios, segments and call linkage for this company ship in the next release.

Line2018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-302019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-302023-09-302023-12-312024-03-312024-06-302024-09-302024-12-312025-03-312025-06-302025-09-302025-12-312026-03-312026-06-30
Revenue from operations26,489.467,224.176,937.637,740.1929,065.918,374.368,123.358,154.8532,837.507,585.258,553.138,836.7833,498.149,718.749,625.939,863.0638,654.4910,761.7610,952.2811,240.9743,885.6811,940.8412,192.4112,380.7048,496.8512,652.7513,291.3913,675.4652,578.4413,851.4014,478.3115,520.5458,462.0415,299.88
Other income838.76199.75351.15193.061,025.49213.02200.85119.88635.98153.79255.78314.95835.52152.52222.89432.51921.512.1485.22173.88634.52204.44293.61250.201,354.19532.55354.00465.621,965.04464.46469.92578.841,971.72723.62
Total income27,328.227,423.927,288.787,933.2530,091.408,587.388,324.208,274.7333,473.487,739.048,808.919,151.7334,333.669,871.269,848.8210,295.5739,576.0010,763.9011,037.5011,414.8544,520.2012,145.2812,486.0212,630.9049,851.0413,185.3013,645.3914,141.0854,543.4814,315.8614,948.2316,099.3860,433.7616,023.50
Cost of materials consumed4,462.601,217.361,065.831,432.975,782.701,335.831,474.051,495.775,515.231,518.841,459.881,427.606,153.131,562.101,584.941,713.737,049.122,000.602,017.341,859.697,777.571,852.491,665.451,709.666,904.331,557.011,638.721,408.316,449.101,771.591,621.511,813.487,389.022,026.28
Purchases of stock-in-trade2,731.38787.78812.47721.512,519.38810.23851.13842.373,414.37683.32881.69868.343,175.17963.14873.58792.373,410.03910.83881.05887.293,571.50679.961,006.82796.493,466.15997.43875.101,238.694,147.951,047.981,087.79922.423,811.531,019.50
Changes in inventories of finished goods, WIP and stock-in-trade230.70101.69-120.6111.18-433.11311.73-57.32-138.15300.85-232.56-195.2437.45-638.22124.1963.34134.52-107.61-11.23-190.3256.69-686.91225.72114.82230.79292.13120.99180.3893.54150.31-4.81273.43209.20343.13-82.62
Employee benefit expense5,367.051,433.001,470.321,494.985,967.091,540.401,620.941,549.126,362.351,759.041,705.291,720.456,862.231,758.741,806.271,850.917,300.832,074.852,004.562,037.078,296.032,402.042,364.362,363.329,429.062,454.622,477.702,552.289,973.122,801.662,764.792,892.0011,418.863,227.23
Finance costs517.57130.90129.53144.79555.25104.0683.9362.96302.7351.9533.2826.10141.4335.0935.9518.97127.3513.6919.3946.18172.0080.8849.2934.73238.4761.5469.1751.51231.3674.8099.8678.36338.9199.67
Depreciation, depletion and amortisation1,499.84401.64426.51471.051,753.25457.13473.28546.992,052.78495.92498.60531.942,079.95503.22530.37553.682,143.74588.00609.95659.952,529.43651.32632.82622.142,556.64655.13625.91630.562,575.39700.55729.50732.332,937.85738.72
Other expenses8,089.602,077.642,178.411,926.668,922.262,380.562,444.812,564.3410,254.942,013.102,508.232,376.809,454.462,489.492,667.862,765.2010,604.402,902.323,283.103,396.5113,280.703,448.863,861.583,803.6115,382.053,915.084,180.534,373.6216,586.273,933.324,203.744,734.9517,768.104,691.82
Total expenses22,898.746,150.015,962.466,203.1425,066.826,939.946,890.826,923.4028,203.256,289.616,891.736,988.6827,228.157,435.977,562.317,829.3830,527.868,479.068,625.078,943.3834,940.329,341.279,695.149,560.7438,268.839,761.8010,047.5110,348.5140,113.5010,325.0910,780.6211,382.7444,007.4011,720.60
Profit before exceptional items and tax4,429.481,273.911,326.321,730.115,024.581,647.441,433.381,351.335,270.231,449.431,917.182,163.057,105.512,435.292,286.512,466.199,048.142,284.842,412.432,471.479,579.882,804.012,790.883,070.1611,582.213,423.503,597.883,792.5714,429.983,990.774,167.614,716.6416,426.364,302.90
Exceptional items-950.500.00-1,214.380.00-1,214.380.000.000.00-260.64-3,633.330.000.00-4,306.14-631.070.000.00-4,566.820.000.000.00-171.45-322.870.00-69.81-494.320.000.00-316.17-677.85-818.000.00-489.48-1,307.48-204.09
Profit before tax3,478.981,273.91111.941,730.113,810.201,647.441,433.381,351.335,009.59-2,183.901,917.182,163.052,799.371,804.222,286.512,466.194,481.322,284.842,412.432,471.479,408.432,481.142,790.883,000.3511,087.893,423.503,597.883,476.4013,752.133,172.774,167.614,227.1615,118.884,098.81
Current tax590.74163.86218.91270.92600.88146.06266.03327.62822.80245.91-31.20244.94514.69395.57197.78335.391,075.50188.99152.26283.43847.59468.10390.10432.321,439.45552.25567.21558.862,772.03870.151,030.52826.073,554.361,188.01
Deferred tax254.450.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Total tax expense845.19163.86218.91270.92600.88146.06266.03327.62822.80245.91-31.20244.94514.69395.57197.78335.391,075.50188.99152.26283.43847.59468.10390.10432.321,439.45552.25567.21558.862,772.03870.151,030.52826.073,554.361,188.01
Profit from continuing operations2,633.791,110.05-106.971,459.193,209.321,501.381,167.351,023.714,186.79-2,429.811,948.381,918.112,284.681,408.652,088.732,130.803,405.822,095.852,260.172,188.048,560.842,013.042,400.782,568.039,648.442,871.253,030.672,917.5410,980.102,302.623,137.093,401.0911,564.522,910.80
Profit from discontinued operations, after tax0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Share of profit of associates and joint ventures-25.441.01-1.871.84-1.46-4.73-4.18-4.33-14.833.58-5.62-4.70-12.33-4.61-2.39-4.52-16.54-2.46-4.27-7.29-47.90-7.39-15.68-7.49-38.41-10.746.66-4.56-15.35-9.75-12.14-19.92-55.87-9.57
Profit for the period2,608.351,111.06-108.841,461.033,207.861,496.651,163.171,019.384,171.96-2,426.231,942.761,913.412,272.351,404.042,086.342,126.283,389.282,093.392,255.902,180.758,512.942,005.652,385.102,560.549,610.032,860.513,037.332,912.9810,964.752,292.873,124.953,381.1711,508.652,901.23
attributable to owners of the parent2,161.551,111.06-218.821,241.852,665.421,387.481,064.09913.523,764.93-1,655.601,812.791,852.482,903.821,444.172,047.012,058.803,272.732,060.882,262.222,166.018,473.582,022.542,375.512,523.759,576.382,835.623,040.162,903.3810,929.042,278.633,117.953,368.8111,479.422,894.79
attributable to non-controlling interests446.80128.55109.98219.18542.44109.1799.08105.86407.03-770.63129.9760.93-631.47-40.1339.3367.48116.5532.51-6.3214.7439.36-16.899.5936.7933.6524.89-2.839.6035.7114.247.0012.3629.236.44
Other comprehensive income, net of tax523.251,652.062,224.85-2,091.381,679.99-103.89514.48461.562,120.83371.05-506.08-99.69-146.03464.94-308.3479.21557.21944.52724.58748.392,256.57216.67219.25424.941,142.1341.39417.75117.94912.41127.421,415.43780.523,826.741,509.15
Total comprehensive income3,131.602,763.122,116.01-630.354,887.851,392.761,677.651,480.946,292.79-2,055.181,436.681,813.722,126.321,868.981,778.002,205.493,946.493,037.912,980.482,929.1410,769.512,222.322,604.352,985.4810,752.162,901.903,455.083,030.9211,877.162,420.294,540.384,161.6915,335.394,410.38
Property, plant and equipment——————————————————10,531.32—10,390.38—10,101.21—10,192.32—10,098.21—10,035.94—10,407.11—11,114.11—
Capital work-in-progress——————————————————805.71—963.35—1,017.33—1,107.73—1,150.12—1,234.34—1,354.73—1,380.65—
Investment property——————————————————0.00—0.00———————————0.00—
Goodwill——————————————————7,041.46—8,712.71—8,920.08—8,598.95—8,771.19—8,939.42—9,279.02—9,833.08—
Other intangible assets——————————————————5,397.13—5,317.03—4,753.26—4,420.11—4,163.93—3,610.92—12,123.48—11,875.08—
Intangible assets under development——————————————————577.51—4,009.81—4,117.24—4,246.15—5,284.48—5,409.62—1,561.29—1,671.08—
Biological assets other than bearer plants——————————————————0.00—0.00———————————0.00—
Investments accounted for using the equity method——————————————————276.42—389.39—371.72—442.61—478.24—448.73———0.00—
Non-current investments——————————————————4,506.60—5,068.09—4,885.39—5,998.62—6,158.28—4,248.97—3,920.05—3,789.07—
Non-current loans——————————————————0.58—0.61—0.40—0.85—0.45—2.79—2.92—1.76—
Non-current trade receivables——————————————————0.00—0.00———————————0.00—
Other non-current financial assets——————————————————197.74—165.29—121.36—117.95—176.91—177.04—117.20—66.61—
Non-current financial assets——————————————————4,704.92—5,233.99—5,007.15—6,117.42—6,335.64—4,428.80—4,040.17—3,857.44—
Deferred tax assets, net——————————————————3,641.15—3,164.24—3,191.72—4,103.65—4,173.55—4,407.55—3,975.33—4,046.46—
Non-current tax assets, net——————————————————0.00—0.00—0.00—0.00———0.00—0.00———
Other non-current assets——————————————————2,476.99—2,679.35—2,607.65—2,758.96—1,554.85—960.79—797.95—1,116.13—
Regulatory deferral account debit balances——————————————————0.00———0.00———————————
Total non-current assets——————————————————35,452.61—40,860.25—40,087.36—41,987.90—42,010.21—39,476.11—43,539.08—44,894.03—
Inventories——————————————————9,874.78—10,513.05—9,956.41—9,868.29—9,935.65—10,243.33—10,442.20—11,492.93—
Current investments——————————————————8,473.93—9,372.61—7,611.24—8,584.54—11,107.19—13,656.10—15,623.01—20,933.45—
Trade receivables——————————————————12,200.75—11,438.51—11,302.65—11,249.37—12,941.99—13,046.11—15,396.01—15,509.67—
Cash and cash equivalents——————————————————4,296.25—4,623.73—5,403.10—9,285.65—8,012.54—10,268.77—10,022.35—9,770.51—
Bank balances other than cash equivalents——————————————————1,064.83—1,146.56—1,818.91—1,235.03—1,002.46—1,062.85—2,235.07—1,832.57—
Current loans——————————————————184.92—41.32—43.11—65.02—47.40—48.38—51.69—52.70—
Other current financial assets——————————————————753.60—764.51—934.09—917.20—633.18—1,740.66—1,520.45—1,403.69—
Current financial assets——————————————————26,974.28—27,387.24—27,113.10—31,336.81—33,744.76—39,822.87—44,848.58—49,502.59—
Current tax assets, net——————————————————0.00—0.00—0.00—0.00———0.00—0.00———
Other current assets——————————————————2,153.82—1,961.65—2,263.14—2,228.01—2,388.44—2,527.86—4,845.65—2,864.77—
Assets classified as held for sale——————————————————0.00—21.40—21.15—41.87—36.60—30.41—30.99—30.90—
Total current assets——————————————————39,002.88—39,861.94—39,332.65—43,433.11—46,068.85—52,594.06—60,136.43—63,860.29—
TOTAL ASSETS——————————————————74,455.49—80,743.59—79,441.16—85,462.88—88,115.66—92,100.58—103,706.50—108,785.22—
Equity share capital——————————————————239.93—239.93—239.93—239.93—239.93—239.93—239.93—239.93—
Other equity——————————————————52,878.00—55,755.45—59,585.71—63,426.82—68,874.97—71,978.09—77,579.79—83,330.16—
Equity attributable to owners of the parent——————————————————53,117.93—55,995.38—59,825.64—63,666.75—69,114.90—72,218.02—77,819.72—83,570.09—
Non-controlling interests——————————————————3,246.18—3,320.09—3,371.24—3,439.22—264.75—267.93—306.87—309.65—
Total equity——————————————————56,364.11—59,315.47—63,196.88—67,105.97—69,379.65—72,485.95—78,126.59—83,879.74—
Non-current borrowings——————————————————0.00—0.00—0.00—1.33—1.33—2.52—2.43—31.26—
Non-current trade payables——————————————————0.00—0.00—0.00———————————
Other non-current financial liabilities——————————————————451.36—563.70—317.50—302.29—427.18—366.42—938.21—992.42—
Non-current financial liabilities——————————————————451.36—563.70—317.50—303.62—428.51—368.94—940.64—1,023.68—
Non-current provisions——————————————————357.27—342.91—361.56—413.89—403.77—465.04—457.17—512.18—
Deferred tax liabilities, net——————————————————32.22—31.69—35.66—155.06—188.76—192.44—383.45—378.02—
Deferred government grants, non-current——————————————————0.00—0.00—————————————
Other non-current liabilities——————————————————549.04—582.82—506.39—499.94—459.75—394.00—383.39—369.56—
Regulatory deferral account credit balances——————————————————0.00———————————————
Total non-current liabilities——————————————————1,389.89—1,521.12—1,221.11—1,372.51—1,480.79—1,420.42—2,164.65—2,283.44—
Current borrowings——————————————————3,806.91—6,197.88—1,487.90—2,844.36—2,079.79—1,867.11—4,683.49—4,050.35—
Trade payables——————————————————5,108.76—5,681.52—5,699.51—5,653.30—5,732.45—6,184.34—6,705.56—7,333.80—
of which dues to micro and small enterprises————————————————————————————0.00—0.00—0.00—
Other current financial liabilities——————————————————1,782.28—1,721.17—1,540.96—1,632.39—2,432.78—2,084.66—2,268.71—2,756.26—
Current financial liabilities——————————————————10,697.95—13,600.57—8,728.37—10,130.05—10,245.02—10,136.11—13,657.76—14,140.41—
Other current liabilities——————————————————772.62—642.72—664.75—1,084.46—704.21—1,169.79—1,196.79—1,187.53—
Current provisions——————————————————4,943.31—5,354.38—5,165.22—5,357.56—5,714.35—6,155.13—7,265.08—5,944.06—
Current tax liabilities, net——————————————————287.61—308.71—464.21—411.70—591.01—733.18—1,295.63—1,350.04—
Deferred government grants, current——————————————————0.00—0.00—————————————
Liabilities associated with assets held for sale——————————————————0.00—0.62—0.62—0.63—0.63———————
Total current liabilities——————————————————16,701.49—19,906.38—15,022.55—16,983.77—17,254.59—18,194.21—23,415.26—22,622.04—
Total liabilities——————————————————18,091.38—21,428.12—16,244.28—18,356.91—18,736.01—19,614.63—25,579.91—24,905.48—
TOTAL EQUITY AND LIABILITIES——————————————————74,455.49—80,743.59—79,441.16—85,462.88—88,115.66—92,100.58—103,706.50—108,785.22—
Depreciation and amortisation——————————————1,033.59—2,143.74—1,197.95—2,529.43—1,284.14—2,556.64—1,281.04—2,575.39—1,430.05—2,937.85—
Finance costs——————————————71.04—127.35—33.08—172.00—130.17—238.47—130.71—231.36—174.66—338.91—
Interest income——————————————195.39—553.37—121.62—384.54—380.27—1,022.91—591.64—1,230.13—507.34—915.00—
Dividend income——————————————173.90—215.33—26.38—146.45—25.28—103.30—35.89—66.90—13.84—59.40—
Fair value gains / losses——————————————157.36—361.95—177.50—161.30—152.82—227.72—-67.04—-133.78—-102.27—-876.10—
Impairment loss / reversal——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—295.30—12.50—0.00—
Share-based payments——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Unrealised foreign exchange losses / gains——————————————-71.24—-17.20—230.66—336.81—188.38—-249.92—-24.76—-336.67—-634.10—-797.10—
Undistributed profits of associates——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Provisions, current——————————————427.41—4,543.68—-4,185.12—-3,803.86—-201.63—3.69—340.21—811.78—1,027.65—-229.96—
Provisions, non-current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Other non-cash items——————————————1.67—11.59—29.01—191.98—17.07—227.61—65.87—198.74—225.15—252.87—
Other items whose cash effects are investing or financing——————————————182.45—116.22—-63.59—-137.97—-29.45—-319.91—-135.44—-412.95—-261.79—0.00—
Other adjustments to reconcile profit——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Total adjustments to reconcile profit——————————————450.98—3,534.00—-5,172.46—-2,939.26—893.91—2,616.53—-1,012.57—796.80—-2,152.61—-385.76—
(Increase) / decrease in inventories——————————————322.38—306.95—-606.75—-1,202.20—474.66—598.81—55.11—-183.97—424.78—-52.30—
(Increase) / decrease in trade receivables, current——————————————-828.61—-1,342.26—-1,399.29—-953.17—116.49—352.89—-1,633.10—-1,602.05—-2,035.92—-2,008.76—
(Increase) / decrease in trade receivables, non-current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
(Increase) / decrease in other current assets——————————————-20.19—14.11—-475.54—-215.81—-442.58—-383.90—66.34—-59.32—-2,396.89—-209.56—
(Increase) / decrease in other non-current assets——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
(Increase) / decrease in other financial assets, current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
(Increase) / decrease in other financial assets, non-current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
(Increase) / decrease in other bank balances——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Increase / (decrease) in trade payables, current——————————————144.74—369.92—724.63—1,182.37—-49.67—249.72—64.85—527.97—553.82—1,057.38—
Increase / (decrease) in trade payables, non-current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Increase / (decrease) in other current liabilities——————————————-600.33—-2,333.35—-687.00—-669.15—-340.94—240.92—-528.83—182.03—-49.07—175.41—
Increase / (decrease) in other non-current liabilities——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Increase / (decrease) in other financial liabilities, current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Increase / (decrease) in other financial liabilities, non-current——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Cash generated from operations——————————————4,541.71—8,015.32—-475.19—6,469.17—6,165.93—13,704.42—6,008.81—14,548.93—5,187.77—14,733.12—
Dividends received (operating)——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Interest paid (operating)——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Interest received (operating)——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Income taxes paid, net of refunds——————————————514.60—-969.22—463.92—1,509.84—447.27—1,569.44—-290.34—476.84—406.75—2,313.94—
NET CASH FROM OPERATING ACTIVITIES——————————————4,027.11—8,984.54—-939.11—4,959.33—5,718.66—12,134.98—6,299.15—14,072.09—4,781.02—12,419.18—
Purchase of property, plant and equipment——————————————981.16—1,495.04—1,076.02—2,085.58—957.72—2,201.81—697.50—2,128.58—2,388.44—3,609.37—
Proceeds from sale of property, plant and equipment——————————————23.29—60.61—11.94—21.01—16.85—30.84—0.00—61.01—47.65—96.12—
Purchase of intangible assets——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from sale of intangible assets——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Purchase of intangible assets under development——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Purchase of investment property——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from sale of investment property——————————————0.00—0.00—0.00—0.00—0.00—0.00—25.94—0.00—0.00—0.00—
Purchase of other long-term assets——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from sale of other long-term assets——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Acquisition of subsidiaries and businesses——————————————0.00—739.57—0.00—4,685.82—143.32—143.32—243.11—272.83—3,405.13—3,405.13—
Disposal of subsidiaries and businesses——————————————23.84—23.84—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Purchase of equity and debt instruments of other entities——————————————7,397.66—24,150.62—9,315.96—21,964.23—11,144.56—29,091.04—15,800.96—32,308.70—10,698.83—30,804.06—
Sale of equity and debt instruments of other entities——————————————7,291.57—20,702.08—9,385.93—20,896.84—13,671.34—30,094.47—13,408.06—29,417.54—10,147.84—26,167.41—
Purchase of interests in joint ventures——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Sale of interests in joint ventures——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Loans and advances made to other parties——————————————7.68—7.68—0.00—0.00—0.00—20.70—3.34—3.38—0.00—0.00—
Repayment of loans and advances by other parties——————————————0.00—14.04—0.00—0.00—0.00—0.00—32.00—32.00—0.00—0.00—
Payments for futures, forwards, options and swaps——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Receipts from futures, forwards, options and swaps——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Interest received (investing)——————————————33.37—76.30—58.28—317.93—23.54—613.20—428.23—803.75—375.93—704.66—
Dividends received (investing)——————————————104.62—133.83—17.66—132.40—93.00—99.14—35.89—66.02—13.84—59.40—
Income taxes paid (investing)——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Government grants received——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
NET CASH FROM INVESTING ACTIVITIES——————————————-1,067.36—-5,724.74—-1,356.00—-7,943.68—993.70—-690.20—-2,583.96—-5,306.16—-6,690.69—-11,344.05—
Proceeds from issue of shares——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from other equity instruments——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from exercise of stock options——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Payments to acquire or redeem own shares——————————————184.30—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Payments on other equity instruments——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from changes in ownership of subsidiaries——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Payments for changes in ownership of subsidiaries——————————————0.00—185.70—0.00—0.00—0.48—0.00—0.00—0.00—0.00—3.80—
Proceeds from debentures, notes and bonds——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
Proceeds from borrowings——————————————948.00—1,656.77—2,746.11—8,159.78—1,721.11—4,715.66—3,220.70—3,361.70—4,152.80—5,322.07—
Repayment of borrowings——————————————2,578.56—4,293.48—0.00—3,030.12—6,425.66—8,105.59—3,995.53—4,392.04—1,473.88—3,410.19—
Payment of lease liabilities——————————————0.00—128.65—60.74—134.62—88.27—123.10—54.66—134.51—84.01—151.37—
Payment of finance lease liabilities——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00———————
Dividends paid——————————————481.99—2,169.19—719.97—2,519.73—961.21—2,900.71—1,201.06—3,617.30—1,320.04—3,937.80—
Interest paid (financing)——————————————43.01—73.21—9.59—99.24—122.29—219.03—125.29—223.82—174.04—331.46—
Income taxes paid (financing)——————————————0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—0.00—
NET CASH FROM FINANCING ACTIVITIES——————————————-2,339.86—-5,193.46—1,955.81—2,376.07—-5,876.80—-6,710.16—-5,058.05—-7,905.82—1,100.83—-2,512.55—
Net change in cash before exchange differences——————————————619.89—-1,933.66—-339.30—-608.28—835.56—4,734.62—-1,342.86—860.11—-808.84—-1,437.42—
Effect of exchange rate changes on cash——————————————54.93—168.88—127.30—723.76—-56.19—-72.70—69.75—123.01—562.42—939.16—
NET CHANGE IN CASH AND CASH EQUIVALENTS——————————————674.82—-1,764.78—-212.00—115.48—779.37—4,661.92—-1,273.11—983.12—-246.42—-498.26—
Closing cash and cash equivalents per cash flow statement————————————————4,508.25—4,296.25—————9,285.65———10,268.77—10,022.35—9,770.51—
Basic earnings per share9.004.09-0.915.1811.115.784.433.8115.69-6.907.567.7212.106.008.508.6013.608.609.409.0035.308.409.9010.5039.9011.8012.7012.1045.609.5013.0014.0047.8012.10
Diluted earnings per share9.004.09-0.915.1811.115.784.433.8115.69-6.907.567.7212.106.008.508.6013.608.609.409.0035.308.409.9010.5039.9011.8012.7012.1045.609.5013.0014.0047.8012.10
Face value per share1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00719,780.901.001.001.001.001.00
Share price at period end495.10564.00623.25430.50475.45400.95389.45432.55352.30472.95500.45592.35597.80675.45818.25845.70914.75830.60948.651,001.40983.101,051.601,158.651,259.451,620.551,520.851,926.701,886.351,734.701,675.701,594.301,719.701,757.201,862.50
Shares outstanding2,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.002,388,208,657.00
Promoter and promoter group, %——————————————54.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.4854.48
Foreign institutions, %——————————————————16.0016.8716.8916.4816.7917.0717.7217.2318.0218.0517.9617.2616.5516.1215.9314.53
of which foreign portfolio investors, % (pre-2025 taxonomy)——————————————0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00—————
of which foreign portfolio investors category I, % (2025 taxonomy)—————————————————————————————16.5015.8415.4015.3314.15
Domestic institutions, %——————————————————19.7119.1419.2419.7519.6719.5218.8319.2818.6118.5518.7019.5020.2320.8221.1122.18
of which mutual funds, %——————————————11.7211.8011.6311.8412.2212.4612.9113.1613.0712.9312.2112.7812.1112.2412.2112.6312.4112.0911.9612.84
of which insurance companies, %——————————————9.598.677.947.526.365.555.125.125.065.025.064.914.944.714.855.095.966.576.837.02
Non-institutions, %——————————————11.7211.5311.0610.919.829.519.399.299.068.928.979.018.898.928.878.778.738.588.488.81
Public, %——————————————45.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.5245.52
Total shares, as filed——————————————2,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.002,399,334,970.00
Claims agreeing within 2%————————————0.000.000.000.000.002.000.002.002.002.001.002.002.000.000.001.001.000.001.002.003.002.00
Claims within 10%————————————3.002.002.002.002.000.003.004.003.003.004.002.001.001.002.001.001.001.003.002.001.000.00
Claims diverging————————————0.000.000.000.000.000.000.001.003.001.001.002.003.000.000.001.000.000.000.001.002.001.00
Adjusted, non-statutory measures quoted————————————0.000.000.000.000.000.000.001.001.001.001.001.001.000.000.002.000.000.001.001.001.000.00
Segment or subset claims————————————0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Operating margin as stated————————————0.240.290.280.260.270.270.270.270.270.280.270.280.250.280.290.290.290.310.310.310.300.29
Filed margin, best-matching definition————————————0.250.300.290.250.260.270.280.280.280.290.280.300.250.280.280.280.280.290.290.310.300.29
Forward-looking statements carrying a number————————————1.001.000.001.003.000.001.001.003.000.000.000.003.000.001.000.004.003.001.000.003.000.00
Guidance raised————————————0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Guidance lowered or narrowed————————————0.000.000.000.000.001.000.000.001.000.000.000.000.000.000.000.000.000.001.000.000.000.00
Guidance maintained————————————0.000.000.000.000.000.000.001.000.000.001.000.000.000.000.000.000.000.000.000.000.000.00
One-time, exceptional or non-recurring items called out————————————1.000.002.002.001.002.002.001.003.002.003.000.000.002.003.001.000.003.005.004.001.000.00
Confidence ratio (confidence words / confidence + caution words)————————————0.430.670.440.610.730.400.730.620.670.580.881.000.770.600.610.550.570.730.670.850.500.53

Earnings calls

23 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 23 documents here); elsewhere sentences render unattributed.

KindDatePeriodServedAttribution rate
TRANSCRIPT202106022021-03-31yes
TRANSCRIPT202108062021-06-30yes
TRANSCRIPT202111112021-09-30yes
TRANSCRIPT202202032021-12-31yes
TRANSCRIPT202206022022-03-31yes
TRANSCRIPT202208032022-06-30yes
TRANSCRIPT202211052022-09-30yes
TRANSCRIPT202302012022-12-31yes
TRANSCRIPT202305312023-03-31yes
TRANSCRIPT202308092023-06-30yes
TRANSCRIPT202311082023-09-30yes
TRANSCRIPT202402062023-12-31yes
TRANSCRIPT202405292024-03-31yes
TRANSCRIPT202408072024-06-30yes
TRANSCRIPT202411042024-09-30yes
TRANSCRIPT202502062024-12-31yes
TRANSCRIPT202505292025-03-31yes
TRANSCRIPT202508062025-06-30yes
TRANSCRIPT202511112025-09-30yes
TRANSCRIPT202602042025-12-31yes
TRANSCRIPT202605052026-03-31yes
TRANSCRIPT202605292026-03-31yes
TRANSCRIPT202608062026-06-30yes

Model workbook

Download SUNPHARMA_model_v2.xlsx — 3199 sourced cells each with a Provenance row (doc_id, sha256, element, contextRef, period, value as filed, locator), 3748 formula cells; SHA-256 a81118dbe88f4d7e…

Commentary — cross-call tabulation

QuarterThemeManagement sentencesAnalyst sentencesManagement share
Q1FY22AI and technology100.0053
Q1FY22Capex and capacity000.0
Q1FY22Capital allocation000.0
Q1FY22Competition440.0214
Q1FY22Credit quality000.0
Q1FY22Currency and macro200.0107
Q1FY22Demand and volumes110.0053
Q1FY22Deposits and liquidity000.0
Q1FY22Distribution and persistency320.016
Q1FY22Margins and costs640.0321
Q1FY22People and attrition000.0
Q1FY22Pricing and realisation1350.0695
Q1FY22Raw materials and input costs000.0
Q1FY22Regulation and policy100.0053
Q1FY23AI and technology000.0
Q1FY23Capex and capacity340.0148
Q1FY23Capital allocation300.0148
Q1FY23Competition310.0148
Q1FY23Credit quality010.0
Q1FY23Currency and macro310.0148
Q1FY23Demand and volumes4120.0197
Q1FY23Deposits and liquidity000.0
Q1FY23Distribution and persistency000.0
Q1FY23Margins and costs280.0099
Q1FY23People and attrition000.0
Q1FY23Pricing and realisation660.0296
Q1FY23Raw materials and input costs000.0
Q1FY23Regulation and policy200.0099
Q1FY24AI and technology000.0
Q1FY24Capex and capacity120.0047
Q1FY24Capital allocation010.0
Q1FY24Competition410.0186
Q1FY24Credit quality210.0093
Q1FY24Currency and macro330.014
Q1FY24Demand and volumes330.014
Q1FY24Deposits and liquidity000.0
Q1FY24Distribution and persistency420.0186
Q1FY24Margins and costs310.014
Q1FY24People and attrition000.0
Q1FY24Pricing and realisation630.0279
Q1FY24Raw materials and input costs000.0
Q1FY24Regulation and policy110.0047
Q1FY25AI and technology000.0
Q1FY25Capex and capacity320.0197
Q1FY25Capital allocation000.0
Q1FY25Competition310.0197
Q1FY25Credit quality030.0
Q1FY25Currency and macro200.0132
Q1FY25Demand and volumes670.0395
Q1FY25Deposits and liquidity000.0
Q1FY25Distribution and persistency210.0132
Q1FY25Margins and costs470.0263
Q1FY25People and attrition000.0
Q1FY25Pricing and realisation520.0329
Q1FY25Raw materials and input costs000.0
Q1FY25Regulation and policy100.0066
Q1FY26AI and technology000.0
Q1FY26Capex and capacity130.0042
Q1FY26Capital allocation100.0042
Q1FY26Competition210.0085
Q1FY26Credit quality100.0042
Q1FY26Currency and macro200.0085
Q1FY26Demand and volumes330.0127
Q1FY26Deposits and liquidity000.0
Q1FY26Distribution and persistency310.0127
Q1FY26Margins and costs670.0254
Q1FY26People and attrition000.0
Q1FY26Pricing and realisation410.0169
Q1FY26Raw materials and input costs100.0042
Q1FY26Regulation and policy360.0127
Q1FY27AI and technology000.0
Q1FY27Capex and capacity210.008
Q1FY27Capital allocation400.016
Q1FY27Competition100.004
Q1FY27Credit quality000.0
Q1FY27Currency and macro300.012
Q1FY27Demand and volumes1040.04
Q1FY27Deposits and liquidity000.0
Q1FY27Distribution and persistency000.0
Q1FY27Margins and costs560.02
Q1FY27People and attrition010.0
Q1FY27Pricing and realisation340.012
Q1FY27Raw materials and input costs000.0
Q1FY27Regulation and policy100.004
Q2FY22AI and technology000.0
Q2FY22Capex and capacity420.0191
Q2FY22Capital allocation240.0096
Q2FY22Competition310.0144
Q2FY22Credit quality000.0
Q2FY22Currency and macro200.0096
Q2FY22Demand and volumes410.0191
Q2FY22Deposits and liquidity000.0
Q2FY22Distribution and persistency200.0096
Q2FY22Margins and costs1080.0478
Q2FY22People and attrition000.0
Q2FY22Pricing and realisation320.0144
Q2FY22Raw materials and input costs120.0048
Q2FY22Regulation and policy100.0048
Q2FY23AI and technology000.0
Q2FY23Capex and capacity320.0145
Q2FY23Capital allocation020.0
Q2FY23Competition300.0145
Q2FY23Credit quality010.0
Q2FY23Currency and macro300.0145
Q2FY23Demand and volumes010.0
Q2FY23Deposits and liquidity100.0048
Q2FY23Distribution and persistency100.0048
Q2FY23Margins and costs460.0193
Q2FY23People and attrition000.0
Q2FY23Pricing and realisation140.0048
Q2FY23Raw materials and input costs000.0
Q2FY23Regulation and policy100.0048
Q2FY24AI and technology000.0
Q2FY24Capex and capacity150.0063
Q2FY24Capital allocation040.0
Q2FY24Competition400.0252
Q2FY24Credit quality010.0
Q2FY24Currency and macro200.0126
Q2FY24Demand and volumes220.0126
Q2FY24Deposits and liquidity000.0

Guidance items

quartermetricdirectionsentencepage
Q4FY21othernanFor the full year FY21, the specialty business has grown over previous year despite the sharp reduction of sales in Q1 on account of the global pandemic.8
Q4FY21othernanFor the full year, R&D investments was Rs. 21,499 million accounting for about 6.5% of sales.9
Q4FY21othernanAnd lastly on the guidance for FY22.9
Q4FY21othernanGiven the uncertainties of the pandemic in the near term, we are refraining from giving a guidance for FY22.9
Q4FY21othernanOne is, total R&D expenses will go up and within that the percentage of the money spent on innovative R&D also is likely to go up.12
Q4FY21othernanSince we’re not giving any specific guidance, but generally we’ve tried to keep our12
Q4FY21othernanSo, general guidance is that what you see as a significant reduction in the marketing spend in all markets is likely to go up.13
Q4FY21othernanWe don’t have clarity because this was launched only towards the end of April…. even May has not closed for me, so, difficult to assess impact, fingers crossed 13
Q4FY21othernanHowever, having said that, we also launched our own authorized generic and we have locked up a few customers whom we have targeted for our share of the market.13
Q4FY21othernanAnd hopefully this time we should be able to clear it successfully, that’s the focus.14
Q4FY21othernanSo, we will get some short-term benefit in next financial year.17
Q1FY22othernanIt is already approved by the USFDA and we expect to commercialize it in the US in the Oct-Dec 2021 quarter.7
Q1FY22othernanOur expectation is that WINLEVI could have far more broad-based appeal, so for us to be able to handle two acne products in the same thing like you thought it w9
Q1FY22volumenanSo, Japan, I think we are in the process of getting entry into hospitals because unlike many other countries, Japan still has restrictions on COVID and medical 11
Q1FY22othernanHe is asking AG, authorized generic, I think it will be in the generic sales.12
Q1FY22othernanNo, we shared a period that hopefully by next year or in subsequent year, it will become positive.13
Q1FY22othernanI mean if we are able to gain market share and grow, then hopefully we should be able to and I think that I am happy with the progress that we are making.13
Q1FY22pricingnanSo at any point of time, there are products which are, let us say, likely to see a price increase, at the same point of time, there are products which are likel17
Q1FY22othernanBecause current COVID status across different markets is very different and we have no understanding of how that is likely to impact the business and I am talki18
Q1FY22othernanLet us say, even in India, we are looking at a potential third wave and we have no understanding of how severe that wave will be, so in such a situation to give18
Q1FY22othernanSo, when we say normalized, I mean it is up from the COVID times, but I don’t think it is back to where it should be in a pre- COVID environment.20
Q1FY22othernanSo, two ways of looking at the whole thing and your second question was share of ILUMYA, the IL-23 market, I think don’t recall the exact number, but in the bal20
Q2FY22othernanI don’t think we ever said that there’ll be a break even across the board next year.12
Q2FY22othernanNo, no real guidance really, we don’t give those details, business-by-business of course.12
Q2FY22othernanWe have indicated that the product that we have chosen is a product which is likely to be in the third wave of biosimilars, which means that potential patent ex20
Q2FY22othernanNo I really cannot give any guidance on that.20
Q2FY22othernanWe have to find creative ways of getting back to where we should be and keep moving forward.22
Q2FY22othernanSo, we stand with the same guidance as we progress.24
Q3FY22othernanAnd I think the visibility I have as of now, going ahead, is also we don't look at it as each quarter, but average for each quarter should be in the same range 13
Q3FY22othernanSo, rather than answer it as a next quarter question, I would look at enough headroom for the businesses to grow their own franchises.13
Q3FY22othernanI think our sense is that the steady state R&D should be around 8%-9%.16
Q3FY22othernanAnd I think depending on how the clinical trial costs continue, and how we capture the clinical trial costs, it will require significant investments going forwa17
Q3FY22othernanI think this year we haven't given any specific guidance.17
Q3FY22othernanSo we should be able to launch this shortly.19
Q3FY22revenue growthnanIt's not a very large product, but the sales as well as the growth of the product are in public domain, so you should be able to see that.19
Q3FY22othernanBut this quarter has been much better and I think the next quarter we will be able to improve further.22
Q3FY22othernanHopefully, I think we should be able to break this drought of potential acquisitions that we've seen in last few years in next maybe one or two years.23
Q4FY22othernanOur India formulations sales for the full year FY22 were Rs. 127,593 million recording a strong 23.4% growth over previous year.6
Q4FY22othernanOur overall US business grew by 12% to US$ 1,526 million for the full year FY22 driven mainly by the strong performance of our specialty business.7
Q4FY22othernanOur branded formulation revenues in Emerging Markets were at about US$ 905 million for the full year, up by about 16% year-on-year.8
Q4FY22othernanWe feel reasonably comfortable that we should be able to do quite well in these litigations.10
Q4FY22othernanOur hope is to capitalize on that and to make this into a meaningful product for the specialty business going forward.11
Q4FY22pricingnanI think hopefully; we should be able to offset some of the cost increases with our ability to take a price increase in the marketplace.17
Q4FY22othernanSo, to that extent, we expect India businesses to get adjusted for that growth.18
Q4FY22othernanIf I look at it from a medium to long-term perspective, I think growth will be driven by a combination of organically growing the products that we have, whereas18
Q1FY23otherLOWEREDLower R&D spending is basically a timing issue and we expect it will gain momentum and be in-line with our guidance in the coming quarters.7
Q1FY23othernanAs to the first part, internally, I am clear when we would be likely to launch, but on our calls, we don't give product wise details when exactly we are launchi14
Q1FY23othernanWe have not given any specific guidance, but we have no major investment.15
Q1FY23pricingnanAnd as of today, as I understand that there are 25 companies which has launched the generic products and the pricing is in the range of Rs. 9-10 for 50 milligra16
Q1FY23othernanSo, at the outset, we want to clarify that we have not given any annual target or guidance of global specialty sales.17
Q1FY23othernanAs such, we have not given any guidance on any specific individual business.17
Q1FY23othernanI think you should factor everything that we've given within our guidance.17
Q1FY23othernanIt's a mixture of how we expect all our businesses to perform, that will include specialty, generic, all markets.17
Q1FY23othernanWe also said at that time, that we are looking at products in the third wave of approvals, in the sense, that we want to be in time for the launch along with pa18
Q1FY23othernanHopefully, we should be able to close all these issues in 12-months.21
Q1FY23othernanIt's more an expectation of how Ilumya will grow, is part of our total guidance.22
Q2FY23othernanWith new indications expected in future, the current growth trajectory of Ilumya would be sustained.7
Q2FY23capexnanWith improving access coupled with geographical expansion into other markets, we expect Winlevi to continue to grow.7
Q2FY23othernanI think we are on track to meet our obligations and launch.9
Q2FY23marginnanGenerally, we don't guide for EBITDA and margins, but broad guidance is that our focus would be to find a way to improve our overall profitability.10
Q2FY23othernanAnd you will see that this is just a blip that is not to be expected to go into the future.11
Q2FY23othernanAll I will say is what I said earlier, we are on track as for whatever we have agreed to with the innovator, and fingers crossed.13
Q2FY23othernanYes, I think you are right, even though on absolute terms, it is going up, in percentage terms, it’s not as per the guidance.13
Q2FY23othernanI think we have guided that we expect the R&D spending in the next two quarters to go up.13
Q2FY23othernanSo, I think we are trying to help you understand without giving specific guidance.14
Q2FY23othernanOn a lighter side, I think Kirti will respond, but maybe it will help me if you can do his review from next quarter.14
Q2FY23othernanSo, I think the idea is to find a way to increase and that's also possibly the reason for the delta between our guidance and our actual spend.16
Q2FY23othernanHowever, as we said that we are not giving any specific guidance on other expenses or margins.17
Q2FY23othernanAnd I think we are on track to do that.18
Q2FY23othernanSo, we don't wish to give any specific guidance on up to which period we expect exclusivity.20
Q2FY23othernanI think next quarter onwards, we will see increase as we used to that's my personal sense.21
Q2FY23othernanSo, I think our guidance is 6% to 8%.21
Q2FY23othernanAnd I think we are not changing the guidance at this point.21
Q2FY23othernanWhen you say target market, you are referring to doctors?21
Q2FY23othernanSo, as we said earlier, no, we are not giving any guidance on this, but based on what you said we should all go on long holiday so that business will take care 22
Q2FY23othernanAnd as per our internal working also, it is also expected to go up as we move forward.24
Q2FY23othernanAbhishek has joined us as Head of Investor Relations and will be taking over the IR responsibilities from the next quarter onwards.24
Q3FY23othernanWe should be able to update the status of this trial in our next call.7
Q3FY23othernanThe R&D investments have increased compared to Q2, and we expect a continued ramp-up of the same.7
Q3FY23othernanR&D investments are likely to increase, both for our specialty and generic businesses.7
Q3FY23othernanYes, I think we have guided that we had challenges in terms of ramping up the clinical studies because of the COVID, and subsequently, because of the war in Rus9
Q3FY23othernanIt's not the next quarter, it will get addressed.10
Q3FY23othernanAnd there is a significant overlap between the HCPs that we meet and the HCPs who are likely to be treating12
Q3FY23othernanThat guidance we will give next year. because I think we will look at the -- all the products in different stages of development, like what I also shared is, we13
Q3FY23otherMAINTAINEDAnd I think we had made some changes to our co-pay plan and then we had improvement in the access, so, I'm pretty confident that, the growth trajectory we will 14
Q3FY23othernanWe shared at the time of sharing the information about Halol, is that based on this, we expect the impact to be less than 3% of the total sales.20
Q3FY23othernanAnd we are not changing or revising our guidance because of this.20
Q3FY23othernanThe transaction has to close, which we expect to close probably in the first quarter of this calendar year.22
Q3FY23othernanSo Abhay, I think we've given some guidance in the past?22
Q3FY23othernanWe are on track for launch.23
Q3FY23othernanBut we don't give guidance beyond the next year.24
Q3FY23othernanWe believe that we've now put in place an appropriate focus and structure so that we should be able to meet the expectation of the agencies.26
Q3FY23othernanSo hopefully, I think with the rationalization of valuation, we should be able to do something.29
Q4FY23othernanLet me take you through the performance of our India business: Our India formulations sales for the full year FY23 were Rs.136,031 million, recording 6.6% growt6
Q4FY23othernanOur overall US business grew by 10.3% to US$1,684 million for the full year FY23, driven mainly by the strong performance of our specialty business.7
Q4FY23othernanOur branded formulations revenues in emerging markets were at about US$983 million for the full year, up by about 8.6% year-on-year.7
Q4FY23othernanNo, I think our current guidance is that we should be filing the product by second quarter, which I think because of the FDA hold on 12 milligram, we are relook9
Q4FY23othernanAnd based on that, once we have clarity we will give you some guidance as to by what time we can come to market.9
Q4FY23othernanWe've already received EIR and we believe that in a gradual and phased manner, we should be able to start selling products out of10
Q4FY23othernanAs we shared in the readout, it will normalize as a percentage of sales going forward.10
Q4FY23otherLOWEREDNo, I think we are on the lower end of the overall R&D guidance.13
Q4FY23othernanUnfortunately, we couldn't do that this quarter, we will start doing it from next quarter as a part of readout only.14
Q4FY23othernanSo, I mean, getting coverage for any product is always a challenge and it's a challenge that we are expecting to meet.21
Q4FY23othernanSo, that's factored in our guidance.22
Q4FY23othernanIt's an achievable guidance.22
Q4FY23othernanSo, we are not giving a separate guidance on that, because we don't know by what time, what products we want to bring back and we might be able to protect the e22
Q4FY23marginnanI think we don't guide for overall profitability because there are so many moving parts.23
Q1FY24othernanSo if I see the underlying base business and the prescription trends of all our major products other than Levulan, I think we are on the right trajectory.7
Q1FY24othernanI think as on today, you should consider the full year guidance.8
Q1FY24othernanSo in our Q4 call, we already said that the sales and distribution in previous calls that these costs have some catch up and unlikely to escalate on the same pa8
Q1FY24revenue growthnanThere may be sales-related growth in these expenses going forward.8
Q1FY24othernanBut also since it's an additional indication, in the other geographies, we should be able to get that filed in a relatively short time.12
Q1FY24othernanShanghvi already mentioned that we're working towards the various clinical trials of various candidates, what we have, and we are on track to achieve R&D guidan16
Q1FY24othernanConcert is part of our R&D guidance.16
Q1FY24othernanAs of now, for our range of products, I haven't seen any big opportunities, which can swing the pendulum, so to say.20
Q2FY24othernanI think as on today, you should presume the guidance.7
Q2FY24othernanI think that should be the focus.8
Q2FY24othernanThe return we expect to normalcy will be gradual, although we are not giving any time frame to normalization.9
Q2FY24othernanNo, I think the reason why we don't share detailing because we don't want to give future guidance on something that can change at many points of time.13
Q2FY24otherMAINTAINEDSo because we try and see that whatever guidance we give for the year, we are able to maintain and deliver.13
Q2FY24othernanSo I would say that we are exploring new areas but without diluting our focus on our core prescription business which we see a good potential going forward.14
Q3FY24othernanSo I mean there will be additional investment based on the trajectory of the products that you see in the budgets that we take for next year.6
Q3FY24othernanSo what we have said is that the Phase II study on GL0034 will start in the second half of next year.10
Q3FY24othernanBut it's going to be an important market for Ilumya going forward.10
Q3FY24othernanSo when we share the next year's guidance, we will share the R&D guidance also.11
Q3FY24othernanSo hopefully, we will touch the low end of the guidance.11
Q3FY24othernanSo there's no need for us to, at this point of time, revise the guidance because it's not something where we are consistently significantly higher.14
Q3FY24othernanAnd looking at some of the corrections which have taken place, I think we see some interesting opportunity that we should be able to work on.14
Q3FY24othernanYour question on next year is very difficult for us to predict what the market will be next year.15
Q4FY24othernanOur India formulation sales for the full year FY '24 were INR148,893 million, recording 9.5% growth over previous year.4
Q4FY24othernanOur overall U.S. business grew by 10.1% to $1,854 million for the full year FY'24.5
Q4FY24othernanOur branded formulation revenues in Emerging Markets were $1.041 billion for the full year, up by 5.9% year-on-year.5
Q4FY24othernanBut otherwise, the overall guidance is a consolidated guidance for all businesses.7
Q4FY24othernanSo we are on track to launch it post the PDUFA date.8
Q4FY24othernanBut we are on track as of now.8
Q4FY24othernanNow we have multiple patents and we feel that we should be able to protect the product for a much longer period of time.10
Q4FY24revenue growthnanFrom the overall perspective for FY '25 outlook, we have given the revenue guidance.11
Q4FY24marginnanAt this point of time, we are not giving any EBITDA margin guidance for FY '25.11
Q4FY24othernanSecondly, I think over a period of time, we should be able to get our new indication of psoriatic arthritis.13
Q4FY24othernanWe are not giving any guidance on margins at this point of time.13
Q4FY24othernanAnd in Europe, if you get good reimbursement and you have good marketing infrastructure, you should be able to at least successfully ensure that the product ben14
Q4FY24othernanSo the overall guidance, which Mr.15
Q4FY24othernanWe believe that increased business that we will get, we should be able to adjust for the increased marketing spend, except in some onetime costs.17
Q4FY24othernanSo we already mentioned that tax expense should be seen on an annual basis.17
Q4FY24othernanAnd it's likely to inch up as we move forward year after year.17
Q4FY24othernanSo our focus is to find a way to give you a guidance for this year, and our effort would be to see that we meet the guidance.18
Q4FY24othernanAnd I think the overall guidance we have presumes in fact of the current challenges that we have in the facilities.18
Q1FY25othernanSo, I think the idea is that once we are clear, which should be shortly, we will request FDA for a re-audit of the facility.9
Q1FY25othernanIt is already there, but it is expected to go up when we actually launch the product there.10
Q1FY25othernanWe have shared the, what you call details about when we expect to file for this product.12

Claims reconciled to filings

QuarterMetricClaimedKindAnchorAnchor valueVerdictSource
Q4FY21operating margin23.2 %ratioEBITDA / total income0.2501CLOSE_WITHIN_10PCTDate_20210602_Sun Pharmaceutic p5
Q4FY21operating margin23.2 %ratioEBITDA / total income0.2501CLOSE_WITHIN_10PCTDate_20210602_Sun Pharmaceutic p6
Q4FY21operating margin24.5 %ratioEBITDA / total income0.2501CLOSE_WITHIN_10PCTDate_20210602_Sun Pharmaceutic p6
Q1FY22operating margin28.7 %ratioEBITDA / total income0.3012CLOSE_WITHIN_10PCTDate_20210806_Sun Pharmaceutic p5
Q1FY22operating margin28.7 %ratioEBITDA / total income0.3012CLOSE_WITHIN_10PCTDate_20210806_Sun Pharmaceutic p5
Q2FY22operating margin26.8 %ratioEBITDA / total income0.2897CLOSE_WITHIN_10PCTDate_20211111_Sun Pharmaceutic p4
Q2FY22operating margin27.7 %ratioEBITDA / total income0.2897CLOSE_WITHIN_10PCTDate_20211111_Sun Pharmaceutic p6
Q3FY22revenue growth21 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220203_Sun Pharmaceutic p4
Q3FY22operating margin26.1 %ratioEBIT / core revenue0.252CLOSE_WITHIN_10PCTDate_20220203_Sun Pharmaceutic p4
Q3FY22revenue growth3 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220203_Sun Pharmaceutic p5
Q3FY22operating margin27.2 %ratioEBIT / core revenue0.252CLOSE_WITHIN_10PCTDate_20220203_Sun Pharmaceutic p5
Q3FY22revenue growth4 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220203_Sun Pharmaceutic p6
Q3FY22revenue growth6 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220203_Sun Pharmaceutic p7
Q4FY22operating margin26.5 %ratioEBITDA / core revenue0.2598CLOSE_WITHIN_10PCTDate_20220602_Sun Pharmaceutic p5
Q4FY22operating margin24.3 %ratioEBITDA / total income0.2567CLOSE_WITHIN_10PCTDate_20220602_Sun Pharmaceutic p6
Q4FY22revenue growth2.3 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220602_Sun Pharmaceutic p6
Q4FY22revenue growth5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220602_Sun Pharmaceutic p7
Q1FY23revenue growth10 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220803_Sun Pharmaceutic p4
Q1FY23revenue growth29 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220803_Sun Pharmaceutic p4
Q1FY23operating margin26.8 %ratioEBITDA / total income0.2682AGREESDate_20220803_Sun Pharmaceutic p4
Q1FY23revenue growth2 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20220803_Sun Pharmaceutic p4
Q1FY23operating margin26.8 %ratioEBITDA / total income0.2682AGREESDate_20220803_Sun Pharmaceutic p5
Q2FY23revenue growth27.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20221105_Sun Pharmaceutic p4
Q2FY23operating margin27 %ratioEBITDA / total income0.2756CLOSE_WITHIN_10PCTDate_20221105_Sun Pharmaceutic p4
Q2FY23revenue growth12.4 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20221105_Sun Pharmaceutic p4
Q2FY23operating margin27 %ratioEBITDA / total income0.2756CLOSE_WITHIN_10PCTDate_20221105_Sun Pharmaceutic p5
Q2FY23operating margin26.9 %ratioEBITDA / total income0.2756CLOSE_WITHIN_10PCTDate_20221105_Sun Pharmaceutic p5
Q3FY23revenue growth28.4 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230201_Sun Pharmaceutic p3
Q3FY23operating profit / EBITDA30,037 millionmoneyderived EBITDA31776000000.0CLOSE_WITHIN_10PCTDate_20230201_Sun Pharmaceutic p5
Q3FY23operating margin26.7 %ratioEBITDA / total income0.2784CLOSE_WITHIN_10PCTDate_20230201_Sun Pharmaceutic p5
Q3FY23revenue growth15.2 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230201_Sun Pharmaceutic p5
Q3FY23profit after tax21,660 millionmoneyPROFIT_AFTER_TAX21807500000.0AGREESDate_20230201_Sun Pharmaceutic p5
Q3FY23operating profit / EBITDA30,037 millionmoneyderived EBITDA31776000000.0CLOSE_WITHIN_10PCTDate_20230201_Sun Pharmaceutic p5
Q3FY23operating margin26.7 %ratioEBITDA / total income0.2784CLOSE_WITHIN_10PCTDate_20230201_Sun Pharmaceutic p5
Q3FY23profit after tax21,660 millionmoneyPROFIT_AFTER_TAX21807500000.0AGREESDate_20230201_Sun Pharmaceutic p5
Q3FY23profit after tax64,891 millionmoneyPROFIT_AFTER_TAX21807500000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20230201_Sun Pharmaceutic p6
Q3FY23revenue12.5 millionmoneyREVENUE_FROM_OPERATIONS112409700000.0DIVERGESDate_20230201_Sun Pharmaceutic p7
Q4FY23revenue growth31.7 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230531_Sun Pharmaceutic p4
Q4FY23operating profit / EBITDA116,468 millionmoneyderived EBITDA31754100000.0DIVERGESDate_20230531_Sun Pharmaceutic p5
Q4FY23operating margin26.5 %ratioEBITDA / total income0.2809CLOSE_WITHIN_10PCTDate_20230531_Sun Pharmaceutic p5
Q4FY23profit after tax86,450 millionmoneyPROFIT_AFTER_TAX19829000000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20230531_Sun Pharmaceutic p5
Q4FY23profit after tax84,736 millionmoneyPROFIT_AFTER_TAX19829000000.0DIVERGESDate_20230531_Sun Pharmaceutic p5
Q4FY23operating profit / EBITDA28,021 millionmoneyderived EBITDA31754100000.0DIVERGESDate_20230531_Sun Pharmaceutic p5
Q4FY23operating margin25.6 %ratioEBITDA / total income0.2809CLOSE_WITHIN_10PCTDate_20230531_Sun Pharmaceutic p5
Q4FY23revenue growth19.7 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230531_Sun Pharmaceutic p5
Q4FY23profit after tax19,845 millionmoneyPROFIT_AFTER_TAX19829000000.0AGREESDate_20230531_Sun Pharmaceutic p5
Q4FY23operating margin25.6 %ratioEBITDA / total income0.2809CLOSE_WITHIN_10PCTDate_20230531_Sun Pharmaceutic p6
Q4FY23profit after tax19,845 millionmoneyPROFIT_AFTER_TAX19829000000.0AGREESDate_20230531_Sun Pharmaceutic p6
Q4FY23revenue growth2.1 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230531_Sun Pharmaceutic p6
Q1FY24revenue33,318 millionmoneyREVENUE_FROM_OPERATIONS119408400000.0DIVERGESDate_20230809_Sun Pharmaceutic p4
Q1FY24operating profit / EBITDA33,318 millionmoneyderived EBITDA35362100000.0CLOSE_WITHIN_10PCTDate_20230809_Sun Pharmaceutic p4
Q1FY24operating margin27.9 %ratioEBITDA / total income0.2912CLOSE_WITHIN_10PCTDate_20230809_Sun Pharmaceutic p4
Q1FY24revenue growth15.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230809_Sun Pharmaceutic p4
Q1FY24profit after tax23,454 millionmoneyPROFIT_AFTER_TAX20056500000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20230809_Sun Pharmaceutic p4
Q1FY24profit after tax20,225 millionmoneyPROFIT_AFTER_TAX20056500000.0AGREESDate_20230809_Sun Pharmaceutic p4
Q1FY24operating margin27.8 %ratioEBITDA / total income0.2912CLOSE_WITHIN_10PCTDate_20230809_Sun Pharmaceutic p4
Q1FY24profit after tax20,225 millionmoneyPROFIT_AFTER_TAX20056500000.0AGREESDate_20230809_Sun Pharmaceutic p4
Q1FY24revenue growth6.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20230809_Sun Pharmaceutic p5
Q2FY24operating margin26.1 %ratioEBITDA / total income0.2782CLOSE_WITHIN_10PCTDate_20231108_Sun Pharmaceutic p4
Q2FY24revenue31,794 millionmoneyREVENUE_FROM_OPERATIONS121924100000.0DIVERGESDate_20231108_Sun Pharmaceutic p4
Q2FY24operating profit / EBITDA31,794 millionmoneyderived EBITDA34729900000.0CLOSE_WITHIN_10PCTDate_20231108_Sun Pharmaceutic p4
Q2FY24revenue growth7.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20231108_Sun Pharmaceutic p4
Q2FY24operating margin26.1 %ratioEBITDA / total income0.2782CLOSE_WITHIN_10PCTDate_20231108_Sun Pharmaceutic p4
Q2FY24profit after tax23,755 millionmoneyPROFIT_AFTER_TAX23851000000.0AGREESDate_20231108_Sun Pharmaceutic p4
Q2FY24operating profit / EBITDA65,112 millionmoneyderived EBITDA34729900000.0DIFFERENT_BASIS_LIKELYDate_20231108_Sun Pharmaceutic p4
Q2FY24operating margin27 %ratioEBITDA / total income0.2782CLOSE_WITHIN_10PCTDate_20231108_Sun Pharmaceutic p4
Q2FY24profit after tax47,209 millionmoneyPROFIT_AFTER_TAX23851000000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20231108_Sun Pharmaceutic p4
Q2FY24profit after tax43,981 millionmoneyPROFIT_AFTER_TAX23851000000.0DIFFERENT_BASIS_LIKELYDate_20231108_Sun Pharmaceutic p4
Q2FY24revenue growth9.4 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20231108_Sun Pharmaceutic p5
Q3FY24operating margin28.1 %ratioEBITDA / total income0.2951CLOSE_WITHIN_10PCTDate_20240206_Sun Pharmaceutic p4
Q3FY24profit after tax25,936 millionmoneyPROFIT_AFTER_TAX25605400000.0AGREESDate_20240206_Sun Pharmaceutic p4
Q3FY24profit after tax25,238 millionmoneyPROFIT_AFTER_TAX25605400000.0AGREESDate_20240206_Sun Pharmaceutic p4
Q3FY24operating profit / EBITDA99,880 millionmoneyderived EBITDA37270300000.0DIVERGESDate_20240206_Sun Pharmaceutic p4
Q3FY24operating margin27.4 %ratioEBITDA / total income0.2951CLOSE_WITHIN_10PCTDate_20240206_Sun Pharmaceutic p4
Q3FY24profit after tax73,145 millionmoneyPROFIT_AFTER_TAX25605400000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20240206_Sun Pharmaceutic p4
Q3FY24profit after tax69,218 millionmoneyPROFIT_AFTER_TAX25605400000.0DIVERGESDate_20240206_Sun Pharmaceutic p4
Q3FY24revenue growth12.9 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20240206_Sun Pharmaceutic p5
Q4FY24profit after tax100,707 millionmoneyPROFIT_AFTER_TAX26587400000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20240529_Sun Pharmaceutic p4
Q4FY24profit after tax95,764 millionmoneyPROFIT_AFTER_TAX26587400000.0DIVERGESDate_20240529_Sun Pharmaceutic p4
Q4FY24revenue30,352 millionmoneyREVENUE_FROM_OPERATIONS119829000000.0DIVERGESDate_20240529_Sun Pharmaceutic p4
Q4FY24operating profit / EBITDA30,352 millionmoneyderived EBITDA36410900000.0DIVERGESDate_20240529_Sun Pharmaceutic p4
Q4FY24operating margin25.3 %ratioEBIT / core revenue0.2496AGREESDate_20240529_Sun Pharmaceutic p4
Q4FY24profit after tax27,562 millionmoneyPROFIT_AFTER_TAX26587400000.0CLOSE_WITHIN_10PCTDate_20240529_Sun Pharmaceutic p4
Q4FY24profit after tax26,546 millionmoneyPROFIT_AFTER_TAX26587400000.0AGREESDate_20240529_Sun Pharmaceutic p4
Q4FY24revenue growth7.8 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20240529_Sun Pharmaceutic p5
Q1FY25operating margin28.5 %ratioEBIT / core revenue0.2754CLOSE_WITHIN_10PCTDate_20240807_Sun Pharmaceutic p4
Q1FY25revenue growth8.8 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20240807_Sun Pharmaceutic p5
Q2FY25operating margin29.6 %ratioEBITDA / total income0.3146CLOSE_WITHIN_10PCTDate_20241104_Sun Pharmaceutic p4
Q2FY25operating margin29.1 %ratioEBIT / core revenue0.2759CLOSE_WITHIN_10PCTDate_20241104_Sun Pharmaceutic p4
Q2FY25revenue growth3.2 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20241104_Sun Pharmaceutic p5
Q3FY25profit after tax32,196 millionmoneyPROFIT_AFTER_TAX29129800000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20250206_Sun Pharmaceutic p4
Q3FY25profit after tax29,034 millionmoneyPROFIT_AFTER_TAX29129800000.0AGREESDate_20250206_Sun Pharmaceutic p4
Q3FY25operating profit / EBITDA115,556 millionmoneyderived EBITDA44746400000.0DIFFERENT_BASIS_LIKELYDate_20250206_Sun Pharmaceutic p4
Q3FY25operating margin29.2 %ratioEBIT / core revenue0.2811CLOSE_WITHIN_10PCTDate_20250206_Sun Pharmaceutic p4
Q3FY25profit after tax90,953 millionmoneyPROFIT_AFTER_TAX29129800000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20250206_Sun Pharmaceutic p4
Q3FY25profit after tax87,792 millionmoneyPROFIT_AFTER_TAX29129800000.0DIVERGESDate_20250206_Sun Pharmaceutic p4
Q3FY25revenue growth10.1 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20250206_Sun Pharmaceutic p5
Q4FY25operating margin29 %ratioEBIT / core revenue0.2828CLOSE_WITHIN_10PCTDate_20250529_Sun Pharmaceutic p3
Q4FY25operating margin28.7 %ratioEBIT / core revenue0.2828AGREESDate_20250529_Sun Pharmaceutic p4
Q4FY25revenue growth4.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20250529_Sun Pharmaceutic p6
Q1FY26operating margin31.1 %ratioEBIT / core revenue0.2935CLOSE_WITHIN_10PCTDate_20250806_Sun Pharmaceutic p4
Q1FY26revenue growth5.1 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20250806_Sun Pharmaceutic p5
Q1FY26revenue growth15.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20250806_Sun Pharmaceutic p5
Q2FY26operating profit / EBITDA45,271 millionmoneyderived EBITDA49969700000.0CLOSE_WITHIN_10PCTDate_20251111_Sun Pharmaceutic p3
Q2FY26operating margin31.3 %ratioEBIT / core revenue0.2947CLOSE_WITHIN_10PCTDate_20251111_Sun Pharmaceutic p3
Q2FY26profit after tax31,180 millionmoneyPROFIT_AFTER_TAX31249500000.0AGREESDate_20251111_Sun Pharmaceutic p3
Q2FY26operating profit / EBITDA88,287 millionmoneyderived EBITDA49969700000.0DIFFERENT_BASIS_LIKELYDate_20251111_Sun Pharmaceutic p4
Q2FY26operating margin31.2 %ratioEBIT / core revenue0.2947CLOSE_WITHIN_10PCTDate_20251111_Sun Pharmaceutic p4
Q2FY26profit after tax61,141 millionmoneyPROFIT_AFTER_TAX31249500000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20251111_Sun Pharmaceutic p4
Q2FY26revenue growth10.9 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20251111_Sun Pharmaceutic p5
Q2FY26revenue growth17.7 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20251111_Sun Pharmaceutic p5
Q3FY26operating profit / EBITDA49,485 millionmoneyderived EBITDA55273300000.0DIVERGESDate_20260204_Sun Pharmaceutic p4
Q3FY26operating margin31.9 %ratioEBIT / core revenue0.3089CLOSE_WITHIN_10PCTDate_20260204_Sun Pharmaceutic p4
Q3FY26profit after tax33,688 millionmoneyPROFIT_AFTER_TAX33811700000.0AGREESDate_20260204_Sun Pharmaceutic p4
Q3FY26profit after tax35,367 millionmoneyPROFIT_AFTER_TAX33811700000.0CLOSE_WITHIN_10PCTDate_20260204_Sun Pharmaceutic p4
Q3FY26operating profit / EBITDA1,37,772 millionmoneyderived EBITDA55273300000.0DIFFERENT_BASIS_LIKELYDate_20260204_Sun Pharmaceutic p5
Q3FY26operating margin31.4 %ratioEBIT / core revenue0.3089AGREESDate_20260204_Sun Pharmaceutic p5
Q3FY26profit after tax96,508 millionmoneyPROFIT_AFTER_TAX33811700000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20260204_Sun Pharmaceutic p5
Q3FY26revenue growth21.6 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20260204_Sun Pharmaceutic p7
Q3FY26revenue growth14.5 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20260204_Sun Pharmaceutic p7
Q4FY26revenue growth14.4 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20260505_Sun Pharmaceutic p5
Q4FY26operating margin30 %ratioEBITDA / core revenue0.302AGREESDate_20260505_Sun Pharmaceutic p5
Q4FY26operating profit / EBITDA39,542 millionmoneyderived EBITDA44127000000.0DIVERGESDate_20260529_Sun Pharmaceutic p4
Q4FY26operating margin27.1 %ratioEBITDA / total income0.2928CLOSE_WITHIN_10PCTDate_20260529_Sun Pharmaceutic p4
Q4FY26profit after tax27,140 millionmoneyPROFIT_AFTER_TAX27096600000.0AGREESDate_20260529_Sun Pharmaceutic p4
Q4FY26operating profit / EBITDA1,77,314 millionmoneyderived EBITDA44127000000.0DIVERGESDate_20260529_Sun Pharmaceutic p4
Q4FY26operating margin30.3 %ratioEBITDA / core revenue0.302AGREESDate_20260529_Sun Pharmaceutic p4
Q4FY26profit after tax1,24,015 millionmoneyPROFIT_AFTER_TAX27096600000.0ADJUSTED_MEASURE_NOT_STATUTORYDate_20260529_Sun Pharmaceutic p4
Q4FY26revenue growth17.4 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20260529_Sun Pharmaceutic p5
Q4FY26revenue growth10 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20260529_Sun Pharmaceutic p6
Q1FY27operating profit / EBITDA44,177 millionmoneyderived EBITDA51412900000.0DIVERGESDate_20260806_Sun Pharmaceutic p4
Q1FY27operating margin28.9 %ratioEBIT / core revenue0.2878AGREESDate_20260806_Sun Pharmaceutic p4
Q1FY27profit after tax28,948 millionmoneyPROFIT_AFTER_TAX29012300000.0AGREESDate_20260806_Sun Pharmaceutic p4
Q1FY27revenue growth4.2 %rationot comparable without the prior year quarter in scopenanNO_ANCHORDate_20260806_Sun Pharmaceutic p6
nanoperating margin30 %rationannanNO_QUARTER_IN_FILENAME6fb0611b-17c4-4e4b-8730-63f760 p8